Treatment of premenstrual dysphoric disorder (PMDD) with a novel formulation of drospirenone and ethinyl estradiol

References

• ACOG practice bulletinClinical management guidelines for obstetrician-gynecologists. Premenstrual syndromeObstet Gynecol2000951910636492
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association (APA)Diagnostic and statistical manual of mental disorders19944Washington DCAPA
   Google Scholar
• AngstJSellaroRMerikangasKRThe epidemiology of perimenstrual psychological symptomsActa Psychiatr Scand2001104110611473504
   PubMed Web of Science ®Google Scholar
• ApterDBorsosABaumgartnerWEffect of an oral contraceptive containing drospirenone and ethinylestradiol on general well-being and fluid-related symptomsEur J Contracept Reprod Health Care20038375112725674
   PubMed Web of Science ®Google Scholar
• CasperRFHearnMTThe effect of hysterectomy and bilateral oophorectomy in women with severe premenstrual syndromeJ Obstet Gynecol19901621059
   Google Scholar
• DaltonKPremenstrual syndrome1964LondonHeinemann
   Google Scholar
• Drug facts and comparisons2002St. LouisFacts and Comparisons
   Google Scholar
• DubrovskyBOSteroids, neuroactive steroids and neurosteroids in psychopathologyProg Neuro-psychopharmacol Biol Psychiatry20052916992
   PubMed Web of Science ®Google Scholar
• EndicottJAmsterdamJErikssonEIs premenstrual dysphoria disorder a distinct clinical entity?J Womens Health Gend Based Med199986637910839653
   PubMedGoogle Scholar
• FoidartJMWuttkeWBouwGMA comparative investigation of contraceptive reliability, cycle control and tolerance of two monophasic oral contraceptives containing either drospirenone or desogestrelEur J Contracept Reprod Health Care200051243410943575
   PubMedGoogle Scholar
• FrackiewiczEJShiovitzTMEvaluation and management of premenstrual syndrome and premenstrual dysphoric disorderJ Am Pharm Assoc20014143747
   Google Scholar
• FrankRTThe hormonal causes of premenstrual tensionArch Neurol Psychiatry19312610537
   Google Scholar
• FreemanEWCurrent update of hormonal and psychotropic drug treatment of premenstrual dysphoric disorderCurr Psychiatry Rep200244354012441023
   PubMedGoogle Scholar
• FreemanEWLuteal phase administration of agents for the treatment of premenstrual dysphoric disorderCNS Drugs2004184536815139800
   PubMed Web of Science ®Google Scholar
• FreemanEWRickelsKSondheimerSJA double-blind trial of oral progesterone, alprazolam, and placebo in treatment of severe premenstrual syndromeJAMA19952745177791258
   PubMed Web of Science ®Google Scholar
• FreemanEWKrollRRapkinAEvaluation of a unique oral contraceptive in the treatment of premenstrual dysphoric disorderJ Womens Health Gend Based Med200110561911559453
   PubMedGoogle Scholar
• FuttermanLARapkinAJDiagnosis of premenstrual disordersJ Reprod Med200651Suppl 43495816734318
   PubMed Web of Science ®Google Scholar
• GirdlerSSPedersenCASternRAMenstrual cycle and premenstrual syndrome: Modifiers of cardiovascular reactivity in womenHealth Psychol199312180928500447
   PubMed Web of Science ®Google Scholar
• GirdlerSSStranevaPALightKCAllopregnanolone levels and reactivity to mental stress in premenstrual dysphoric disorderBiol Psychiatry2001497889711331087
   PubMed Web of Science ®Google Scholar
• HalbreichUEndicottJGoldsteinSPremenstrual changes and changes in gonadal hormonesActa Psychiatr Scand198674576863825581
   PubMed Web of Science ®Google Scholar
• HalbreichURojanskyNPalterSEstrogen augments serotonergic activity in postmenopausal womenBiol Psychiatry199537434417786956
   PubMed Web of Science ®Google Scholar
• HuberJFoidartJMWuttkeWEfficacy and tolerability of a monophasic oral contraceptive containing ethinylestradiol and drospirenoneEur J Contracept Reprod Health Care20005253410836660
   PubMedGoogle Scholar
• JohnsonSRMcChesneyCBeanJAEpidemiology of premenstrual symptoms in a non-clinical sample. I. Prevalence, natural history and help-seeking behaviorJ Reprod Med198833340463367333
   PubMed Web of Science ®Google Scholar
• KauraVIngramCDGartsideSEThe progesterone metabolite allopregnanolone potentiates GABA(A) receptor-mediated inhibition of 5-HT neuronal activityEur Neuropsychopharmacol2006in press
   Web of Science ®Google Scholar
• LoboRAStanczykFZNew knowledge in the physiology of hormonal contraceptivesAm J Obstet Gynecol199417014995078178898
   PubMed Web of Science ®Google Scholar
• MichenerWRozinPFreemanEThe role of low progesterone and tension as triggers of perimenstrual chocolate and sweets craving: Some negative experimental evidencePhysiol Behav1999674172010497961
   PubMed Web of Science ®Google Scholar
• ParryBLGernerRHWilkinsJNCSF and endocrine studies of premenstrual syndromeNeuropsychopharmacology19915127371930615
   PubMed Web of Science ®Google Scholar
• ParseyKSPongAAn open-label, multicenter study to evaluate Yasmin, a low-dose combination oral contraceptive containing drospirenone a new progestogenContraception2000611051110802275
   PubMed Web of Science ®Google Scholar
• OelkersWDrospirenone, a progestogen with antimineralocorticoid properties: a short reviewMol Cell Endocrinol20042172556115134826
   PubMed Web of Science ®Google Scholar
• PaolettiAMLelloSFrattaSPsychological effect of the oral contraceptive formulation containing 3 mg of drospirenone plus 30 μg of ethinyl estradiolFertil Steril2004816455115037415
   PubMed Web of Science ®Google Scholar
• ParseyKSPongAAn open-label, multicenter study to evaluate Yasmin, a low-dose combination oral contraceptive containing drospirenone, a new progestogenContraception2000611051110802275
   PubMed Web of Science ®Google Scholar
• PaulSMPurdyRHNeuroactive steroidsFASEB J199262311221347506
   PubMed Web of Science ®Google Scholar
• PearlsteinTBBachmannGAZacurHATreatment of premenstrual dysphoric disorder with a new drospirenone-containing oral contraceptive formulationContraception2005724142116307962
   PubMed Web of Science ®Google Scholar
• RapkinAA review of treatment of premenstrual syndrome and premenstrual dysphoric disorderPsychoneuroendocrinology200328Suppl 3395312892989
   PubMed Web of Science ®Google Scholar
• RapkinAJBiggioGConcasAOral contraceptives and neuroactive steroidsPharmacol Biochem Behav2006in press
   Web of Science ®Google Scholar
• RapkinAJMorganMSoglianoCDecreased neuroactive steroids induced by combined oral contraceptive pills are not associated with mood changesFertil Steril2006851371816580672
   PubMed Web of Science ®Google Scholar
• RedeiEFreemanEWPreliminary evidence for plasma adrenocorticotropin levels as biological correlates of premenstrual symptomsActa Endocrinol1993128536428393259
   PubMedGoogle Scholar
• RubinowDRSchmidtPJGonadal steroid regulation of mood: the lessons of premenstrual syndromeFront Neuroendocrinol200627210616650465
   PubMed Web of Science ®Google Scholar
• SangthawanMTaneepanichskulSA comparative study of monophasic oral contraceptives containing either drospirenone 3 mg or levonorgestrel 150 microg on premenstrual symptomsContraception2005711715639064
   PubMed Web of Science ®Google Scholar
• Schultz-ZehdenBBoschitschEUser experience with an oral contraceptive containing ethinylestradiol 30 mug and drospirenone 3 mg (yasmin®) in clinical practiceTreat Endocrinol20065251616879004
   PubMedGoogle Scholar
• SteinerMBornLDiagnosis and treatment of premenstrual dysphoric disorder: An updateInt Clin Psychopharmacol200015suppl 3S5S1711195269
   PubMed Web of Science ®Google Scholar
• SteinerMStreinerDLSteinbergSThe measurement of premenstrual mood symptomsJ Affect Disord1999532697310404713
   PubMed Web of Science ®Google Scholar
• StrombergJHaageDTaubeMNeurosteroid modulation of allopregnanolone and GABA effect on the GABA-A receptorNeuroscience2005143738116938407
   PubMed Web of Science ®Google Scholar
• van VlotenWAvan HaselenCWThe effect of 2 combined oral contraceptives containing either drospirenone or cyproterone acetate on acne and seborrheaCutis20026921512096825
   PubMedGoogle Scholar
• WangMSeippelLPurdyRHRelationship between symptom severity and steroid variation in women with premenstrual syndrome: Study on serum pregnenolone, pregnenolone sulfate, 5a-pregnane-3, 20-dione and 3a-hydroxy-5a-pregnan-20-oneJ Clin Endocrinol Metab1996811076828772579
   PubMed Web of Science ®Google Scholar
• WatsonNRStuddJWSavvasMThe long-term effects of estradiol implant therapy for the treatment of premenstrual syndromeGynecol Endocrinol19904991072118709
   PubMed Web of Science ®Google Scholar
• WittchenHUBeckerELiebRPrevalence, incidence and stability of premenstrual dysphoric disorder in the communityPsychol Med2002321193211883723
   PubMed Web of Science ®Google Scholar
• YonkersKABrownCPearlsteinTBEfficacy of a new low-dose oral contraceptive with drospirenone in premenstrual dysphoric disorderObstet Gynecol200510649250116135578
   PubMed Web of Science ®Google Scholar